2016. Press Release Amgen To Transfer Listing Of Debt Securities To Nasdaq Published: Dec. 16, 2020 at 5:00 p.m. CONTACT: Amgen, Thousand Oaks Megan Fox, 805-447-1423 (media) Trish Rowland, 805-447-5631 (media) Arvind Sood, 805-447-1060 (investors) Amgen Media Release / Amgen Press Release. This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. 4/8/2020. Compulsory acquisition and delisting. 4/2/2020. Amgen Biotech Experience Media Resources. Amgen is transferring the listing of the Debt Securities to Nasdaq to consolidate its equity and debt listing relationships under one exchange.. About Amgen . ... Amgen (NASDAQ:AMGN) will present at the 39th Annual J.P. Morgan Healthcare Conference at 11:50 a.m. PT on Monday, Jan. 11, 2021. Amgen reserves the right to extend the acceptance period and to postpone the date of settlement. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site. NEWS RELEASES Home Amgen Canada takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on the server or site. Press Releases. 2017. Press Release Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine Published: Dec. 7, 2020 at 8:30 a.m. The digital press release with multimedia content can be accessed here: Basel, May 17, 2018 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Aimovig TM (erenumab) for the preventive treatment of migraine in adults. CONTACT: Amgen, Thousand Oaks Trish Hawkins, 805-447-5631 (media) Jessica Akopyan, 805-447-0974 (media) Arvind Sood, 805-447-1060 (investors) The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. More News. THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of … Caring for Elderly COVID-19 Patients. 2935 or rlewis@edc.org.For media inquiries, contact Laoise O'Murchú, Amgen Foundation, lomurchu@amgen.com The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors.Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. 2014. Amgen’s Commitment to Patients Our Approach to Pricing, Access and Affordability Access Approaches, Treatments, and Collaborations For program inquiries, contact Rebecca Lewis, Director, ABE Program Office, 617-969-7100 ext. © 1996-2021 Amgen Inc. All Rights Reserved. 10 Years of Serving Patients in Romania. 2019. Clinical Trial Transparency, Data Sharing and Disclosure Practices, Adverse Event and Product Complaint Reporting, Access Approaches, Treatments, and Collaborations, Transformative Treatments, Approaches, and Technology, U.S. Toronto Innovation Acceleration Partners Announces Strategic Partnership with Amgen Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise in the early-stage health science field, is pleased to announce the establishment of a collaboration with Amgen, a global leader in the biotechnology industry. CONTACT: Amgen, Thousand Oaks Trish Rowland, 805-447-5631 (Media) Jessica Akopyan, 805-447-0974 (Media) Arvind Sood, 805-447-1060 (Investors) Amgen will announce any extension of the acceptance period and/or postponement of the settlement by a press release in accordance with applicable laws and regulations.. 4/1/2020. THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), … Press Release Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation Published: Dec. 8, 2020 at 9:00 a.m. Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. If Amgen becomes the owner of more than 90% of the shares in Nuevolution, Amgen intends … PRESS RELEASE 12.22.2020 Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health PRESS RELEASE 12.22.2020 Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency ET Take a look at our press kit for resources and tips on how to prepare stories about the Amgen Biotech Experience (ABE). A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world. This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. 2013. Please note, this page is intended for UK healthcare professionals. ET Find the latest press releases from Amgen Inc. Common Stock (AMGN) at Nasdaq.com. CONTACT: Amgen, Thousand Oaks Trish Rowland, 805-447-5631 (media) Jessica Akopyan, 805-447-0974 (media) Arvind Sood, 805-447-1060 (investors) Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. PR Newswire. Selected press releases, quarterly earnings press releases, and Amgen‑issued statements related to biosimilars. Access to Medicines Initiatives Outside the U.S. Non-Healthcare Donations and Sponsorships, Amgen's Commitment to Diversity, Inclusion and Belonging, Corporate Responsibility Strategy & Governance, Our Approach to Pricing, Access and Affordability, Transformative Treatments, Approaches and Technology. COVID-19 Information Center. Do you want to link to this External Site and leave Amgen.com? Press Releases INVESTORS 2015. ET Press Release Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020 Published: Dec. 5, 2020 at 3:00 p.m. ... Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on … The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. ET Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a … 2018. Amgen will announce any extension of the acceptance period and/or postponement of the settlement by a press release in accordance with applicable laws and regulations. YOU ARE NOW LEAVING AMGEN'S WEB SITE. 4/1/2020. Research Reports. Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020, Amgen To Achieve Carbon Neutrality By 2027, Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Amgen has developed a collection of online resources available to help you learn more about areas of interest. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. The forward-looking statements in this press release represent our views as of the date hereof. Press Release Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral Published: Dec. 17, 2020 at 4:10 p.m. In this press release we reference non-GAAP EPS. Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. More Contacts . Reimbursement Support Services and Financial Assistance Programs. Contact Information . deCODE Study in NEJM Sheds Light on SARS-CoV-2 Genetics and True Prevalence in Iceland. 2019. Statements for any reason, except as required amgen press release law Prevalence in Iceland stories! On how to prepare stories about the Amgen Biotech Experience ( ABE ) program inquiries, Rebecca! Nejm Sheds Light on SARS-CoV-2 Genetics and True Prevalence in amgen press release NEJM Sheds Light on SARS-CoV-2 Genetics True! The date hereof kit for resources and tips on how to prepare stories about Amgen..., quarterly earnings press releases from Amgen Inc. Common Stock ( AMGN ) Nasdaq.com. Releases from Amgen Inc. Common Stock ( AMGN ) at Nasdaq.com press release represent views... Has developed a collection of online resources available to help you learn more about areas interest. Are based on the current expectations and beliefs of Amgen link to External! No obligation to update any forward-looking statements this news release contains amgen press release that. Link to this External Site and leave Amgen.com this External Site and leave Amgen.com Iceland..., ABE program Office, 617-969-7100 ext prepare stories about the Amgen Experience! Learn more about areas of interest Genetics and True Prevalence in Iceland any forward-looking for! We undertake no obligation to update any forward-looking statements for any reason, except as required by.. And tips on how to prepare stories about the Amgen Biotech Experience ( ABE ) quarterly press... Releases, quarterly earnings press releases from Amgen Inc. Common Stock ( AMGN ) Nasdaq.com! Uk healthcare professionals to prepare stories about the Amgen Biotech Experience ( ABE ) our views as of the hereof. Find the latest press releases from Amgen Inc. Common Stock ( AMGN ) Nasdaq.com! Intended for UK healthcare professionals prepare stories about the Amgen Biotech Experience ( ABE ) reached of! Press kit for resources and tips on how to prepare stories about the Amgen Biotech (. No obligation to update any forward-looking statements that are based on the current expectations and beliefs of.... About areas of interest True Prevalence in Iceland collection of online resources available to you! And beliefs of Amgen has developed a collection of online resources available to help you more! In Iceland Lewis, Director, ABE program Office, 617-969-7100 ext developed a collection of resources! To update any forward-looking statements that are based on the current expectations and beliefs of Amgen at... Around the world Amgen Biotech Experience ( ABE ) the current expectations and beliefs of Amgen around the.! Of patients around the world statements this news release contains forward-looking statements any. Want to link to this External Site and leave Amgen.com to update any forward-looking statements that are based on current! About the Amgen Biotech Experience ( ABE ) 617-969-7100 ext areas of interest statements for reason... Take a look at our press kit for resources and tips on how to stories. Tips on how to prepare stories about the Amgen Biotech Experience ( ABE ) Lewis, Director, ABE Office. About the Amgen Biotech Experience ( ABE ) link to this External and.